Exchange: NASDAQ·Updated 07:30 PM EST

CALC News

News
all
press releases
What Makes CalciMedica Inc. (CALC) a New Buy Stock
CalciMedica Inc. (CALC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
What Makes CalciMedica Inc. (CALC) a New Buy Stock
CalciMedica Inc. (CALC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
More News
Gainers Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion. CalciMedica (NASDAQ:CALC) shares roseread more...
Benzinga
CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential...
PR Newswire
Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 49.1% to $4.1 during Tuesday's after-market session. The market value of their outstanding shares is at $1.5 million. CalciMedica (NASDAQ:CALC) shares rose 9.8%read more...
Benzinga
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program PR Newswire LA JOLLA, Calif., June 24, 2026...
PR Newswire
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data PR Newswire LA JOLLA, Calif., June 24, 2026 FDA...
PR Newswire
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates...
PR Newswire
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates CalciMedica Reports 2025 Financial Results and Provides Clinical Updates PR Newswire LA JOLLA, Calif., March 3, 2026 Internal...
PR Newswire
CalciMedica said that it has decided to discontinue the trial evaluating its lead product candidate Auxora in patients with Stage 2 or Stage 3 acute kidney injury following a committee recommendation.
Stocktwits

Advertisement|Remove ads.